Amylin/calcitonin receptor (dual)

Assets acting on this target.

Class
Dual amylin/calcitonin receptor agonist (DACRA)

The amylin receptor and the calcitonin receptor are related G-protein-coupled receptors that normally respond to two different pancreatic and thyroid-derived hormones involved in appetite, glucose handling, and bone metabolism. Amylin, released alongside insulin after meals, acts on brain regions that control fullness, slows stomach emptying, and dampens the release of glucagon, a hormone that raises blood sugar. Calcitonin, acting through its own receptor, has overlapping effects on satiety signaling in the brainstem in addition to its classical role restraining bone-resorbing cells. A dual amylin/calcitonin receptor agonist (DACRA) is a synthetic peptide engineered to activate both receptor systems simultaneously, rather than mimicking either hormone alone. The rationale is that combined engagement produces a more pronounced and durable reduction in food intake and body weight, alongside favorable effects on blood glucose regulation, than agonism of either receptor individually. This class is being explored for obesity and for metabolic disease more broadly, including conditions where excess body weight and impaired insulin action co-occur. Because the underlying biology intersects appetite regulation, gastrointestinal motility, and glucose metabolism, DACRAs represent a strategy for addressing multiple facets of metabolic disease through a single, centrally and peripherally acting mechanism.

By indication

Related mechanisms

Amylin/calcitonin receptor (dual) drugs compared

4 drugs, stage by indication
4 drugs acting on Amylin/calcitonin receptor (dual): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
cagrilintideNovo NordiskpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Chronic Kidney Disease
cagrilintide/semaglutideCagriSemaNovo NordiskpeptidePhase 3Phase 3 in Obesity; Phase 3 in Type 2 Diabetes
petrelintideRoche, Zealand PharmapeptidePhase 3Phase 3 in Obesity
BGM1812BrightGene Bio-Medical TechnologypeptidePhase 2Phase 2 in Obesity

← all mechanisms